Novo Nordisk A/S Reports Up to 2.16% HbA1c Reduction with Triple Agonist UBT251 After 24 Weeks in Phase 2 Trial Among Chinese Patients with Type 2 Diabetes The United Laboratories International Holdings Limited and Novo Nordisk A/S have announced encouraging…
Seaport Therapeutics, Founded by PureTech, Reports Science Translational Medicine Publication Highlighting GlyphAllo™ (SPT-300) as a First-in-Class Triglyceride-Mimetic Prodrug Achieving Therapeutic Drug Levels in Humans PureTech Health plc has highlighted a significant scientific milestone achieved by its Founded Entity, Seaport Therapeutics,…
NBDF’s Pathway to Cures Launches Spark Biomedical’s LUNA Trial to Explore Non-Drug Treatment for Heavy Menstrual Bleeding For many women and adolescent girls living with inherited bleeding disorders, heavy menstrual bleeding (HMB) remains one of the most physically and emotionally…
Enhancing Digital Health Capabilities Through Integrated Blended Learning Approaches Across many low- and middle-income countries, the promise of digital health transformation is often constrained by a persistent and complex reality: fragmented systems, overlapping digital tools, and increasing pressure on health…
Roche Launches State-of-the-Art Institute of Human Biology Facility to Advance Next-Generation Human Model Systems in Drug Discovery and Development Roche has officially inaugurated a new state-of-the-art research facility to serve as the home of its Institute of Human Biology (IHB),…
Biogen to Showcase Late-Breaking Phase 2 AMETHYST Data on Litifilimab in Cutaneous Lupus Erythematosus at the 2026 American Academy of Dermatology Annual Meeting Biogen Inc. has announced a series of upcoming scientific presentations at the prestigious American Academy of Dermatology…
Allergan Aesthetics Highlights Shifting Trends in Modern Aesthetic Care Through Global Survey and Enhanced Educational Initiatives Allergan Aesthetics, a division of AbbVie and a globally recognized leader in the field of medical aesthetics, has unveiled a comprehensive new body of…
Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus placebo when added to standard of care in adult patients…
Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Enhancing Economies of Scale from Development to Manufacturing and Direct Commercialization Celltrion announced today that it will immediately incorporate newly announced global regulatory updates aimed at streamlining biosimilar development into its…
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine, announced the publication of a new study in JCO Precision…
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…